Analytical validation of liquid biopsy test for ESR1 mutations offers potential clinical utility by identifying biomarkers that may drive acquired resistance to hormone therapy in breast cancer SAN DIEGO , March 4, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
SAN DIEGO , March 23, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that Interim Chief Financial Officer Mark Foletta has received the CFO
Biocept's CTC Test Identified Approximately 22 Percent of Women With Breast Cancer to Have HER2 Positive CTC After Disease Progression Following a HER2 Negative Diagnosis With Solid Tumor Biopsy
SAN DIEGO , Sept. 23, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces that Lyle Arnold , Ph.D., Chief
Abstracts feature clinical results demonstrating the high sensitivity of Biocept's Target Selector™ platform and the ability to identify mutations that may be missed by tissue biopsyClinical experience study evaluating 2,000 patient samples using Biocept's liquid biopsy tests shows detection of clinically actionable lung cancer mutations consistent with published prevalence rates"AND" marketing campaign highlights the benefits of using both liquid biopsy and tissue biopsy to improve the chances of rapidly identifying clinically actionable biomarkers in cancer patients
Data highlights clinical proof-of-concept for monitoring metastatic testicular cancer using the Company's proprietary CTC assays, as well as validation of Biocept's high sensitivity circulating tumor DNA tests on Thermo Fisher QuantStudio™5 instrument SAN DIEGO , March 15, 2018 /PRNewswire/ --
Clinical study data highlight the ability of Biocept's proprietary liquid biopsy technology to detect and monitor actionable biomarkers and circulating tumor cell counts in the blood and in cerebrospinal fluid of non-small cell lung cancer patients SAN DIEGO , Sept.
Limit of detection of 0.02% or better enables accurate molecular profiling for treatment selection and dynamic monitoring of response to therapy using a simple blood sample SAN DIEGO , Oct. 7, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
Using Target Selector™ to detect HER2 alterations assists physicians in reassessing therapy options over the course of treating patients with metastatic breast cancer SAN DIEGO , Dec. 10, 2020 /PRNewswire/ -- Biocept, Inc . (Nasdaq: BIOC), a leading commercial provider of molecular diagnostic
